Independent report · Private Markets

Scimplify: US$25m Series C

November 7, 2026 · By Somyesh

Sachin Santhosh, co-founder of Scimplify Source: TechCrunch, 14 Oct 2026

Sachin Santhosh, co-founder of Scimplify Source: TechCrunch, 14 Oct 2026

Independent report content

ROUNDSeries C · US$25m all-equity · announced 14 Oct 2026
LEADHitachi Ventures
CO-INVESTORSNew: Henkel, Teknor Apex · Returning: Accel, Bertelsmann India Investments, Omnivore, 3one4 Capital
TOTAL RAISEDAbout US$80m in equity (company); US$54m before this round
VALUATIONNot confirmed by the company; reported at US$250m post-money, up from US$150m in March 2025
REVENUEReported annual run rate of about US$200m (trade press, Sacra); target US$400m run rate within a year. Audited figures not published
MODELDevelops and scales specialty chemicals for global buyers, made by a network of partner factories, run on its SciNode software
USE OF FUNDSUS$7.5m for US expansion and manufacturing network; research; Japan and US customers
COMPANYBengaluru · founded 2023
THE ACCESS POINT Scimplify is private. The Series C was taken by corporate and venture investors. Individuals can reach it only through rare secondary sales or funds that hold it (Accel, 3one4, Omnivore and Bertelsmann India run funds open to Indian and NRI investors through feeder routes).

Executive decision summary

THE BOTTOM LINE Scimplify does not make chemicals itself. It takes a customer's specification, designs the process, qualifies factories in India and elsewhere, and ships the finished product, using software called SciNode to track every batch. The US$25m Series C adds two customers as owners (Henkel, Teknor Apex) and Hitachi as lead, which is a strong sign that buyers trust the model. The reported US$200m run rate looks large next to US$54m raised before this round, but run rate is not audited revenue, and partner-made chemicals carry thin margins and heavy working capital.
WHICH INVESTOR Fits you IF you want exposure to the shift of specialty-chemicals sourcing away from China, can accept private-company illiquidity and a price that already assumes fast growth. Look elsewhere IF you need audited profits or a disclosed valuation.
COMFORT FIT Scimplify = the architect and general contractor who designs a building and hires the best builders, instead of owning the brickworks. Listed Indian specialty-chemical makers (Aarti, SRF, Navin Fluorine) = the brickworks: they own plants, take capital risk and report audited profits. Divis Labs / Syngene = contract makers with a track record in pharma.
THE RUPEIA NUMBER US$25m raised for a reported US$200m run rate. That is 0.125 dollars of new equity per dollar of run-rate sales. It shows how little capital the partner-factory model needs, and how much the business relies on suppliers and customers' credit.

1 CLAIM REGISTER: EVIDENCE GRADING

A = government or regulator record. B = statutory filing. C = independent press. D = company announcement.

ClaimSourceGradeRupeia assessment
US$25m Series C led by Hitachi VenturesTechCrunch (14 Oct 2026); Global Venturing; Argus Partners deal noteCEstablished. All-equity strategic round.
Henkel and Teknor Apex join as investorsArgus Partners; TechCrunchCEstablished. They are also customers.
US$250m post-money valuationTechCrunch citing a person familiar; SacraCReported, not confirmed by Scimplify.
US$40m Series B in March 2025 at US$150mPackaging South Asia; TechCrunchCEstablished. Co-led by Accel and Bertelsmann.
About US$80m lifetime equityCompany statementDCompany figure.
About US$200m annual run rate; US$400m targetSacra; Under30CEO, citing managementDManagement run rate, not audited turnover.
US$7.5m earmarked for US expansionTrade pressCAllocation may change.

2 COMPANY OVERVIEW & FOUNDING STORY

Scimplify was founded in Bengaluru in 2023 (the idea came from a 2022 conversation) by Sachin Santhosh and Salil Srivastava; some sources also name Dheeraj Dhingra as a co-founder. It sells 'chemistry as a service' to buyers of advanced materials, crop chemicals, life-science intermediates and industrial specialties. A buyer sends a specification; Scimplify's chemists develop and prove the process, then move it into partner factories that are audited and qualified, and handle quality, compliance and shipping.

The software layer, SciNode, records process steps, batches and supplier data. Management says this lets it add factories quickly and swap suppliers without changing the product. The pitch to Western and Japanese buyers is a second source of critical materials outside China, with compliant paperwork.

3 TIMELINE

DateEvent
2023Founded in Bengaluru; seed capital raised
2023–24Series A; seed and Series A together raised US$13.5m
Mar 2025US$40m Series B co-led by Accel and Bertelsmann; total raised reaches about US$54m; post-money about US$150m
2025–26Expands partner-factory network and customers in the US, Europe and Japan
14 Oct 2026US$25m Series C led by Hitachi Ventures; Henkel and Teknor Apex join; total about US$80m

4 FUNDING HISTORY & INVESTOR BEHAVIOUR

RoundAmountLead / investorsReported post-money
Seed + Series AUS$13.5m combinedAccel, 3one4, Omnivore and othersNot disclosed
Series B (Mar 2025)US$40mAccel and Bertelsmann India (co-leads)~US$150m
Series C (Oct 2026)US$25mHitachi Ventures; Henkel, Teknor Apex; Accel, Bertelsmann, Omnivore, 3one4 return~US$250m (reported)

Every earlier investor returned in the Series C, which is a positive sign. The new money comes from corporates that buy the product, so a share of demand is tied to the cap table. That helps growth but may give those buyers a say on terms.

RUPEIA CALCULATION US$25m at a US$250m post-money is a 10% stake. The valuation rose 67% in 19 months (US$150m to US$250m). On the reported US$200m run rate, US$250m is 1.25x sales. That is low for software and typical for a trading or contract-manufacturing business.

5 BUSINESS MODEL & UNIT ECONOMICS

Scimplify earns the spread between what the buyer pays and what the partner factory charges, plus development fees. Public sources give no margin. The table shows the economics that decide profitability.

DriverWhat it meansNot disclosed
Gross spreadPrice to customer less factory priceMargin by product
Working capitalRaw materials, inventory and shipping paid before the customer paysDebtor and inventory days
Customer concentrationA few large buyers (including investors) may drive volumeTop-customer share
Factory concentrationDependence on a few qualified plantsPlants used
SciNodeSoftware cost shared across many batchesSoftware revenue, if any
RUPEIA CALCULATION At an illustrative 10% gross margin, US$200m of sales yields US$20m of gross profit; at 5% it yields US$10m. Neither figure is disclosed. The gap shows why the audited accounts matter more than the run rate.

6 MARKET & COMPETITIVE ANALYSIS

PeerModelOverlap
Aarti Industries, SRF, Navin Fluorine (listed)Own plants, backward integrationCompetes for the same Western buyers; carries asset risk
Divi's Laboratories, Syngene (listed)Contract development and manufacturingPharma-led; long track record
Chinese specialty producersScale and low costThe supply that buyers want to diversify from
Univar, Brenntag (listed)Chemical distributionDistributors; less process development
Other Indian platforms (for example Chemcrux, Tradeindia chemicals)Marketplace and sourcingNarrower, trading-focused

The 'China plus one' theme drives demand: Western and Japanese buyers want a second source of critical materials. Scimplify's edge is speed of onboarding new factories; its risk is that listed Indian chemical makers can offer the same supply with their own plants.

7 MOAT ANALYSIS

SourceStrengthComment
Process know-how and customer approvalsMediumQualified products take months to approve; switching is costly for buyers
Customer-investors (Henkel, Teknor Apex, Hitachi)MediumPulls demand but invites bargaining
SciNode dataWeak-mediumUseful; copyable by large chemical distributors
Supplier networkMediumDepends on partner loyalty

8 VALUATION ANALYSIS

Reported post-moneyx US$200m run ratex US$400m target run rate
US$150m (Mar 2025)0.75x0.4x
US$250m (Oct 2026)1.25x0.6x

Rupeia calculation using management's run rate; audited revenue is not published.

If the US$400m target is met at a similar multiple, equity would be worth about US$500m, double today's price. If growth stalls at US$200m, the price rests on margins that are not public.

9 SCENARIO ANALYSIS

ScenarioProbabilityWhat happensOutcome
Bull30%Run rate reaches US$400m with stable margins; US plant startsSeries D or strategic sale above US$600m
Base50%Growth slows to 40–60% a year; margins thinFlat-to-modest up round in 2028
Bear20%Large customer or factory is lost; working capital strainsDown round or forced sale

10 EXIT ANALYSIS

Likely routes are a sale to a global chemicals or materials group, such as one of the customer-investors, or a later Indian listing once audited profits exist. Hitachi, Henkel and Teknor Apex are natural acquirers. A listing needs audited revenue and profits that the public record does not yet show.

11 RISK ANALYSIS: RED FLAG LEDGER & KILL CONDITIONS

RiskSeverityKill condition
Run rate is not audited revenueHighFiled revenue far below US$200m
Thin margins, heavy working capitalHighNegative operating cash flow for two years
Customer-investor concentrationMediumOne buyer above 30% of sales
Chemical safety and compliance failure at a partner plantMediumA shipment recall or regulatory ban
Valuation resetMediumNext round below US$250m

12 INVESTOR CLASS ANALYSIS

HNIs

Direct access is unlikely. Funds with Scimplify exposure are the practical route.

Family offices

A Series D co-investment is the realistic entry; ask for audited FY26 revenue and margin by product.

Institutions

Corporates in chemicals, retail and electronics are natural strategic holders.

NRIs

NRIs can hold unlisted Indian shares under FEMA rules; the company is an Indian entity with international subsidiaries.

13 COMFORT FIT: THE DECISION PAGE

If you want…Best fitCaution
A China-plus-one chemicals platformSCIMPLIFYRun-rate sales, valuation 1.25x
Profitable listed specialty chemicalsAarti, SRF, Navin FluorineOwn plants; cyclical
Contract manufacturing in pharmaDivi's, SyngeneDifferent end market

14 THE EARLY SIGNAL: EVENTS TO WATCH

WhenEventWhy it matters
Nov 2026–Jan 2027FY26 accounts filedFirst audited view of revenue and margins
2027US manufacturing network opensTests the US$7.5m expansion
2027Hitachi, Henkel, Teknor Apex ordersShows investor-customers' volume
2027–28Series DSets the next price

15 RUPEIA FINAL INDEPENDENT VIEW

Scimplify has done what most Indian deep-tech names have not: it has strategic customers paying and investing. The open question is profit. The business is a platform of contracts, not a plant, so margins are thin and cash is tied up in inventory. At 1.25x run-rate sales the price is fair if margins are ordinary and cheap if they are good.

THE RUPEIA NUMBER US$250m reported valuation, 1.25x the reported US$200m run rate.
RUPEIA VERDICT Strategically strong and fairly priced if margins are ordinary. Wait for FY26 accounts before paying a secondary premium.

Frequently asked questions

How much did Scimplify raise?

US$25m in a Series C announced on 14 October 2026, led by Hitachi Ventures.

What is Scimplify's valuation?

Reported at about US$250m post-money, up from US$150m in March 2025. The company has not confirmed it.

Who invested in Scimplify?

Hitachi Ventures, Henkel, Teknor Apex, Accel, Bertelsmann India Investments, Omnivore and 3one4 Capital.

What is Scimplify's revenue?

Management cites an annual run rate of about US$200m. Audited revenue is not published.

What does Scimplify do?

It develops specialty chemicals for global buyers and has them made by qualified partner factories.

Can I buy Scimplify shares?

Only through rare secondary sales or funds that hold it.

Source log

TechCrunch: Scimplify raises US$25m to challenge China's grip on critical materials (14 Oct 2026)

Global Venturing: Hitachi Ventures leads US$25m round in Scimplify

Sacra: Scimplify

Under30CEO: Scimplify raises US$25m

Chemical Weekly

Scimplify website

DISCLAIMER This report is independent research by Rupeia Investments Co. built only from public sources as of the date shown. It is not an offer, solicitation or investment advice, and it is not a recommendation to buy or sell any security. Private-company figures are drawn from filings and media reports and may be revised. Unlisted and private-market investments are illiquid and carry a risk of total loss. Investors should take independent advice.